Nat Commun: A combination of four drugs at low doses may be effective in treating non-small cell lung cancer

, July 4, 2020 /PRNewswire/
-- Many cancertreatments are currently available when high-dose drugs are used to inhibit the specific activity of mutant-affected proteins, a strategy that, in addition to being first effective, can lead totumorscells By developing secondary mutations, secondary mutations are resistant to therapy, thereby enhancing alternative growth pathways and promoting cell avoidance of drug-induced effects, which are the case with non-small cell lung cancer, which is caused by Mutations in EGFR receptors, while eGFR inhibitor-based therapies promote resistance in cancer cellsPicture Source: CC0 Public Domain
In a recent study published in the international journalCommunications Nature, scientists from the IDIBELL-Bellvitge Institute for Biomedical Research and other institutions developed a new therapeutic treatment for non-small cell lung cancer using a low-dose mixed drug (MLDs, Multiple Low Dose, multiple small doses) that appears to simultaneously inhibit the activity of multiple proteins in the same signaling pathways that are so necessary fortumorcellsresearchers say that when we use a combination of four inhibitors, at least 20 percent of the effective dose of the drug is enough to completely block the signaling pathway and cell proliferation, and after studying cell lines in vitro and animal models produced by implanting living tissue into the lungs of mice, the researchers revealed the long-term effects of MLD therapy and did not have the associated toxic effects, although each drug would not produce a single
a synergetic effect at low dosesthe results of this paper, a combination of drugs may work on different components in the necessary communication pathways in tumor cells, both to improve the long-term efficacy
of anti-tumor therapy and to avoid the emergence
of cancer resistance when used at low doses; (BioValleyBioon.com) original origins: Fernandes Neto, J.M., Nadal, E., Bosdriesz, E et al.
Multiple low dose therapy as an effective strategy to treat EGFR-resistant NSCLC tumours .
Nat Commun 11, 3157 (2020) doi: 10.1038/s41467-020-16952-9